ZZ Biotech, LLC
ZZ Biotech LLC is a clinical stage company developing innovative biologic treatments for ischemic stroke and other neurological diseases and wound healing applications including the treatment of diabetic foot ulcers. ZZ Biotech was incepted in 2006 to focus on the development of 3K3A-APC, a novel second-generation variant of a naturally occurring human protein licensed from The Scripps Research Institute. ZZ Biotech’s 3K3A-APC is a genetically engineered variant of recombinant APC, a serine protease. APC has two biochemical pathways in the body. APC exerts anticoagulant activity by inactivation of Factor Va and VIIIa, and it exerts cytoprotective activity primarily through interaction with the endothelial protein C receptor (EPCR) and protease-activated receptor-1 (PAR-1). 3K3A-APC was designed through elegant biochemistry and molecular biology as a safer, “bio-better” version of APC, with greatly reduced anti-coagulant activity.